Additional Assays Increase Exome Sequencing Diagnostic Yield in Rare Neurogenetic Disorders
August 10th 2021Investigators obtained a molecular diagnostic yield of 39% in 66 sequential, unselected individuals with diverse presentations of rare neurogenetic disorders when using a model that integrates additional assays.
Dosing of WVE-004 Treatment Begins In Frontotemporal Dementia and ALS
August 9th 2021Developed by Wave Life Sciences, the trial of the investigational treatment, WVE-004, seeks to identify ideal dose level and frequency in patients with C9orf72-associated amyotrophic lateral sclerosis and FTD.
Direct Transfer to Angiography Suite for LVO Acute Stroke Offers Benefit Over Conventional Workflow
August 8th 2021The direct transfer protocol had greater decreases in the median door-to-arterial puncture time and door-to-reperfusion time in comparison to conventional workflow in acute ischemic stroke care.
Investigating the Future of Wearable Sensors for Automatic Seizure Detection
August 7th 2021Jianbin Tang, data scientist and research leader from IBM Research Australia, and colleagues spoke on findings from their recent study and plans for a newly developed artificial intelligence-based model.
The State of the Alzheimer Disease Pipeline: Eric Reiman, MD
August 6th 2021The executive director of Banner Alzheimer’s Institute commented on ongoing research into amyloid plaque-reducing antibody therapies, the approval of aducanumab, and other initiatives with the ability to impact the treatment of Alzheimer disease.
CNM-Au8 Meets Primary End Point in Phase 2 Parkinson Disease, Multiple Sclerosis Studies
August 5th 2021Homeostatic equilibrium was achieved with CNM-Au8 across essential energetic metabolites, including adenosine triphosphate, intracellular phosphorous, phosphocholine, and phosphorylation potential index.
Pimavanserin Associated With Lower Relapse Risk of DRP, Symptom Reduction
August 5th 2021The phase 3 trial of pimavanserin in dementia-related psychosis, HARMONY, was previous halted due to positive efficacy signs at interim analysis. The drug is currently indicated for use in treating Parkinson disease-related psychosis.
NYU Langone’s Comprehensive Epilepsy Center Elevates Care Standards, Drug Development
August 5th 2021Led by a team of top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stand among the field's most important.
Anti-CD20 Therapy for MS and NMOSD Linked to Lower COVID-19 Antibody Response
August 4th 2021Among independent variables including DMT group, time from COVID-19 infection, total IgG level, age, sex, obesity, and COVID-19 severity, only the anti-CD20 group was associated with decreased odds of positive serology.